Clinical Developments

Cortex has completed a Phase I human safety and tolerability study with CX1739 involving approximately 100 subjects, tested at doses up to 1200mg per day.  The plasma half-life of CX1739 was around 8 hours, and CX1739 exhibited an excellent safety and tolerability profile.  This was followed by the initiation of a Phase IIa pilot study in twenty subjects suffering from sleep apnea.  A second Phase II study will be initiated in adults with ADHD. Before being sold to Biovail, CX717, a structurally related to CX1739, demonstrated efficacy in an adult ADHD population.